XML 271 R214.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Other revenue (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | [2] | Dec. 31, 2022 | [2]
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |  |
Other revenues |  | € 3,205 | € 3,801 | [1] | € 2,910 | [1]
Disclosure of other revenue [Table] |  |
(€ million) | 2024 | 2023(a) | 2022(a)
VaxServe sales of non-Sanofi products | 1,959 | 2,167 | 1,567
COVID-19 vaccine related revenues | — | 509 | 257
Intragroup sales from continuing to discontinued operations (b) | 163 | 188 | 208
Royalties | 121 | 107 | 103
Other(c) | 623 | 534 | 399
Total Biopharma Other revenues | 2,866 | 3,505 | 2,534
Sales / Revenues from Opella products(d) | 339 | 296 | 376
Total Other revenues | 3,205 | 3,801 | 2,910
(a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b)Revenues generated by legal entities within the scope of continuing operations from the manufacture of Opella products on behalf of legal entities within the scope of discontinued operations. (c)This line mainly includes revenues received under agreements for Sanofi to provide manufacturing services to third parties. (d)Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights). |  |  |  |
Biopharma (operating segment) |  |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |  |
Other revenues |  | € 2,866 | 3,505 | [3] | 2,534 | [4],[5]
Royalty income |  | 121 | 107 |  | 103 |
Revenue from COVID-19 vaccine |  | 0 | 509 |  | 257 |
Revenue from intragroup sales from continuing to discontinued operations | [6] | 163 | 188 |  | 208 |
Miscellaneous other revenue | [7] | 623 | 534 |  | 399 |
Revenue from VaxServe sales of non-Sanofi products |  | 1,959 | 2,167 |  | 1,567 |
Opella Business |  |  |  |  |  |
Disclosure of information about major customers and credit risk [line items] |  |  |  |  |  |
Other revenues | [8] | € 339 | € 296 |  | € 376 |
[1] | Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] | (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] | Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[4] | (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[5] | (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax).
[6] | (b)Revenues generated by legal entities within the scope of continuing operations from the manufacture of Opella products on behalf of legal entities within the scope of discontinued operations.
[7] | (c)This line mainly includes revenues received under agreements for Sanofi to provide manufacturing services to third parties.
[8] | (d)Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).

X
- Definition The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_OtherRevenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of income arising from royalties. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueFromRoyalties
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Disclosure of information about major customers and credit risk. + References No definition available. + Details
Name: | sny_DisclosureOfInformationAboutMajorCustomersAndCreditRiskLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of other revenue + References No definition available. + Details
Name: | sny_DisclosureOfOtherRevenueTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Miscellaneous other revenue + References No definition available. + Details
Name: | sny_MiscellaneousOtherRevenue
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue from COVID-19 vaccine + References No definition available. + Details
Name: | sny_RevenueFromCOVID19Vaccine
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue from intragroup sales from continuing to discontinued operations + References No definition available. + Details
Name: | sny_RevenueFromIntragroupSalesFromContinuingToDiscontinuedOperations
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue from VaxServe sales of non-Sanofi products + References No definition available. + Details
Name: | sny_RevenueFromVaxServeSalesOfNonSanofiProducts
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=sny_OpellaBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |